



2023

Interim Report
for the first quarter

January – March 2023

Interim Report for the first quarter of 2023

January 1 – March 31, 2023

The first quarter in figures


- Net sales amounted to TSEK 21,466 (7,076), which corresponds to a growth of 203%.
- The U.S. business demonstrated 399% growth, increasing the U.S. share of global sales to 65%.
- Further acceleration of OssDsign Catalyst, which now represents 41% of total sales in the group.
- Underlying gross margin continued to develop favorably during the quarter, driven by positive product and geography mix.
- Operating profit showed a moderate improvement over previous year, despite strategic investments in clinical programs. Adjusted for the USD hedge revaluation effect, which affects comparability, the improvement came out at MSEK +1.7, or approximately 7% better.
- As operating expenses now start to stabilize, the sales and gross margin development will drive further operating leverage.
- Loss after taxes amounted to TSEK 23,252 (23,953).
- Earnings per share was SEK -0.3 (-0.4).
- Cash flow from current operations was TSEK -28,863 (-23,872), an MSEK -5.0 higher net outflow than in the previous year and a logical consequence of higher sales in the quarter, generating receivables, and higher payments of year-end accruals, with a combined net outflow of MSEK -5.9. In addition, the comparison is further negatively affected by MSEK -1.3 of accounting items relating to USD hedge revaluation.

Important events during the first quarter

- First-in-patient case report of OssDsign Catalyst shows complete spinal fusion 6 months post-surgery.
- OssDsign reaches milestone of 500 patients treated with OssDsign Catalyst in the U.S.
- OssDsign Catalyst 1cc is launched and available in the U.S. market.
- OssDsign reaches commercial milestone of 200 Cranial PSI sold in France
- OssDsign increases operational efficiency and reduces Cranial PSI lead time by up to 40 percent.

Important events after the end of the first quarter

- OssDsign reaches commercial milestone of 750 Cranial PSI sold in Germany.
- 1,000 patients treated with OssDsign Catalyst in the U.S.



Financial overview

	2023	2022	2022
	Jan 1 – Mar 31	Jan 1 – Mar 31	Jan 1 – Dec 31
<i>The group</i>			
Net sales, TSEK	21 466	7 076	56 985
Operating profit, TSEK	-23 697	-24 037	-90 494
Profit for the period, TSEK	-23 252	-23 953	-99 629
Equity ratio, %	70%	75%	71%
Earnings per share, SEK	-0.3	-0.4	-1.7
Average number of employees	510	46.5	482



“ We reported a spectacular 399% growth in our U.S. business with continued acceleration of OssDsign Catalyst ”

Sustainable and accelerating growth

Once again, we report a very strong quarter. We have repeatedly shown solid growth across many quarters, and I am pleased to see that the strategy we established continues to deliver sustainable and accelerating growth. Net sales for the first quarter of 2023 amounted to SEK 21.5 million, which corresponds to a growth of 203% compared to the same period last year, or 177% at constant exchange rates. Most notably, we reported a spectacular 399% growth in our U.S. business with continued acceleration of OssDsign Catalyst.


Exponential U.S. growth

At the end of 2020, we took the strategic decision to expand into Orthobiologics with a synthetic bone graft for spinal fusion and leverage the position as innovation leader established on the back OssDsign Cranial PSI. At the same time, we made the decision to focus on the U.S. market. Since then, we have shown solid growth with sales accelerating on an exponential curve in the last four quarters.

OssDsign Catalyst represented 41% of our overall revenues in the first quarter and the U.S. share of sales increased to 65%.

Continued exponential growth in the U.S

LTM sales, MSEK



OssDsign Cranial PSI sales acceleration in key European markets

Sales of OssDsign Cranial PSI also continue to grow, particularly in our focus markets of Germany and France and, in the first quarter, we reported 74% growth in our Rest of World region. In Germany, we recently reached 750 sold implants with a significant acceleration of sales in the last two years. In France, we reached a commercial milestone during the quarter when we achieved cumulative sales of 200 implants. Since the launch of Cranial PSI in France in 2019, we have won several major public tenders and have secured multiple recurring users. This is a clear example of how we create growth by combining our highly differentiated technology offering with a focused go-to-market model.

The product offering for Cranial PSI has recently been further strengthened by optimizing the manufacturing process and thereby shortening the lead time by up to 40 percent. We can now deliver our highly differentiated, regenerative patient-specific implant within three weeks in all geographical areas. This efficiency improvement means that Cranial PSI will be a more attractive option for cranial surgery in our focus markets, particularly in the U.S.

Mid- and long-term clinical investments

We are still at the beginning of the growth journey which has been accelerated by the scalability of OssDsign Catalyst. In January, we reported that 500 patients had been treated with OssDsign Catalyst, and in the beginning of May, the number had doubled to 1,000 patients. The rapid uptake in the market since launch confirms the product’s large potential, but to fully capture the opportunity, clinical evidence to support its differentiation will be required. Consequently, we are making strategic mid- and long-term investments to produce clinical evidence as cost-effectively as possible.


By combining a small clinical study (TOP FUSION) with a prospective multicenter registry in the U.S. (PROPEL), we will build stronger clinical evidence in a fast and cost-effective way. Whilst these investments of course adversely impact operating profits in the short term, we believe this is a well-balanced approach that will enable us to drive the growth of OssDsign Catalyst, building a substantially bigger and profitable business in the years to come.

The strategy is beginning to pay off, paving way for improved operating result

Thanks to our unique products which are based on the latest material science and therefore have a high degree of appeal to surgeons, we have already established OssDsign at the forefront of the regenerative area in the medical device industry.

Through a continued focus on sales, scalability, and cost-efficiency, it is clear that our strategy is starting to pay off, evidenced by the sustainable and accelerating growth trajectory we have now reported across several quarters, driven principally by our high margin and scalable product, OssDsign Catalyst, in our priority market, the U.S. Naturally, as sales continue to accelerate, there will be positive developments in terms of the operating result.

Morten Henneveld, CEO



Statement of Operations

Based on cutting edge material science, OssDsign develops regenerative bone replacement products that support the body's own healing capabilities and thereby improve clinical outcome in a wide range of orthopedic areas with high unmet clinical needs.

Next generation bone replacement products

Current bone replacements fail to heal a wide range of skeletal defects, leading to poor clinical outcome. OssDsign is focused on two particularly challenging areas where the success rate is far from acceptable today: cranial and spinal surgeries.

OssDsign Cranial PSI – groundbreaking technology for cranial surgeries

OssDsign Cranial PSI is an implant used for patients who have lost a large part of the cranium. The implant is constructed from 3D printed medical-grade titanium covered by a regenerative calcium phosphate composition. While the titanium skeleton reinforces the implant to resist physical and mechanical stress, the unique calcium phosphate composition provides healing and regenerative properties, allowing regrowth of the patient's own bone tissues. Over time, the calcium phosphate composition is replaced with bone, leaving the patient with a well-integrated implant, potentially lasting a lifetime.

To date, OssDsign has post market surveillance data from 1,995 surgeries with OssDsign Cranial PSI, showing an exceptional performance. Many cranial implant technologies are associated with high rates of costly complications and patient suffering. Multiple studies report infection rates above 10%, of which many implants will need to be removed and replaced. In contrast, the observed rate of explantations due to infections in patients who received OssDsign Cranial PSI was only 1.4% at an average follow-up time of 21 months, implying a far lower need for implant revisions, thereby reducing the cost of care for the healthcare system and better patient outcomes.

The global market for cranial implants is estimated to be USD 2.5 billion with an expected CAGR of 7% between 2021–2025, whereof the addressable market for OssDsign's implant products is estimated to be USD 0.4 billion. OssDsign Cranial PSI has regulatory approval in Europe, the U.S. and Japan.

OssDsign Catalyst –

an off-the-shelf nanosynthetic bone graft

Nearly 80% of Americans experience low back pain at some point in their lives and more than 1.5 million undergo spinal surgery each year. Approximately 20% of these surgeries are unsuccessful due to the lack of proper fusion. For a spinal fusion surgery to be successful, two or more vertebrae must fuse and be permanently connected. Bone replacement material plays a crucial role in the fusion as it stimulates bone growth between the vertebrae, but due to the presence of a relatively large gap between the vertebrae proper fusion is challenging to achieve with today's standard treatments.

OssDsign Catalyst is an innovative nanosynthetic bone graft composed of a proprietary nanocrystalline silicates calcium phosphate. Similar to the body's own bone mineral architecture, OssDsign Catalyst provides a favorable bone biology environment for rapid and reliable bone formation.

OssDsign Catalyst is a high gross margin product with great scalability and a large potential in the market for standard procedures, enabling extensive growth. OssDsign Catalyst received FDA clearance in 2020 and was launched in the U.S. in August 2021. The U.S. market for orthobiologics in spinal surgeries is valued at USD 1.8 billion and the global market at USD 2.6 billion, with an expected CAGR of 7% during 2021–2025.

COVID-19 pandemic and post-pandemic impact

OssDsign is continuously monitoring the post-pandemic impact of COVID-19 on its operations, especially as it pertains to staff shortages and delays to hospital approval processes. These continue to remain a challenge for the health care system and could, consequently, also negatively impact the company's result. The underlying demand for OssDsign products in the mid-long term, however, remains intact and OssDsign hope to see a continued improvement of the situation during 2023.

Development of profit and financial position

FIRST QUARTER

Net sales

The OssDsign group Net sales for the first quarter of 2023 amounted to TSEK 21,466 (7,076), which corresponds to a growth of 203% compared to Q1 2022, or 177% in constant currency terms. It is also an increase over the previous quarter, thus making Q1 another all-time-high. In the same period the parent company Net sales amounted to TSEK 14,637 (6,917).

Key drivers of this extraordinary growth were clearly the U.S. and OssDsign Catalyst. Total net sales in the U.S. for the first quarter grew by 399% compared to Q1 2022, which is quite spectacular. We are extremely pleased to see such strong growth numbers in our main market, quarter on quarter, which now constitutes 65% of our total business. In Rest of World, our main European markets Germany and France also contributed with significant growth in the first quarter.

Underlying gross margin continued to develop well in the first quarter, as it has for several quarters now. This is primarily driven by the increased Catalyst share of total sales, which is now 41% of global sales in the quarter, but also by the general increase in U.S. sales.

As the parent company sales are to subsidiaries or direct to the markets, the above description is also applicable to the parent company's sales development.

Operating profit/loss and Net financial items

Operating loss for the period January – March 2023 amounted to TSEK 23,383 (24,037). Other operating income had an insignificant impact on this year's Q1 result, whereas the corresponding positive effect in previous year was considerable at TSEK +1,245, as that figure was affected by accounting items, particularly unrealized exchange rate gains from revaluation of our USD hedge. The Q1 2023 exchange rate effect from revaluation of the USD hedge was marginally negative, due to a lower hedge position as well as a decrease in the USD/SEK balance date rate. Adjusting for the hedge effect, the improvement over previous year came out at MSEK +1.7, showing some early signs of positive operating leverage.

Operating expenses have increased vs the same quarter previous year whilst decreased vs previous quarter. We are investing in significantly growing the business, which means more U.S. presence and increased sales dependent items. In addition, we are making strategic mid to long term investments in clinical programs. As operating expenses now start to stabilize, the sales and gross margin development will drive further operating leverage.

The operating expense decrease vs previous quarter is primarily driven by higher year-end accruals in the comparison period, as is customary in a comparison between Q1 and Q4.

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents amounted to TSEK 124,653 and at the end of the period they were TSEK 95,611. Cash flow from operating activities amounted to TSEK -28,863 (-23,878). The total cash flow for the period was TSEK -29,038 (-24,002), indicating a TSEK -5,036 higher net cash outflow than previous year, as well as higher than Q4 2022. The higher net cash outflow, when measured as the difference in net cash position, is driven partly by accounting entries (MSEK -1.3 difference in the revaluation of the USD cash position) but even more so by the TSEK -5,944 negative net working capital effects from a much higher sales quarter (higher receivables) and the planned payments of year-end accruals from Q4.

A minor investment of TSEK -47 (0) was made in tangible assets in the period.

IMPORTANT EVENTS DURING THE FIRST QUARTER

First-in-patient case report of OssDsign Catalyst shows complete spinal fusion 6 months post-surgery

On January 4, OssDsign announced that a first-in-patient case report from the clinical study TOP FUSION has been published in Biomedical Journal of Scientific & Technical Research. The peer reviewed article presents data showing complete spinal fusion 6 months after surgery with the novel nanosynthetic bone graft OssDsign Catalyst.

OssDsign reaches a milestone of 500 patients treated with OssDsign Catalyst® in the U.S.

On January 9, OssDsign announced that 500 patients have now been treated in the U.S. with the innovative nanosynthetic bone graft, OssDsign Catalyst. Since the launch, awareness of the product has increased exponentially, which is reflected in the growing number of patients who benefit from the treatment. Reaching the 500-patient milestone is a significant achievement in the effort to expand the product's presence in the U.S. market.

OssDsign Catalyst 1cc is launched and available in the U.S. market

On January 10, OssDsign commenced the launch of a new size of OssDsign Catalyst in the U.S. market. The additional volume option of 1 cubic centimeter (cc) is fully available on the market and completes the existing product range of 10, 5, and 2,5 cc, thereby broadening access to new procedures in both the cervical spine and smaller extremities.

OssDsign reaches commercial milestone of 200 Cranial PSI sold in France

On March 14, OssDsign announced that the company had reached the commercial milestone of 200 Cranial PSI sold in France. Since entering the market in late 2019, OssDsign has signed several important tenders in France leading to a significantly accelerated sales during the last year.

OssDsign increases operational efficiency and reduces Cranial PSI lead time by up to 40 percent

On March 20, OssDsign announced that the company has significantly reduced Cranial PSI lead times up to 40 percent through optimizations in the manufacturing process. By delivering on this important milestone, OssDsign enhances the offering and substantially improve the product's competitiveness and growth potential. The reduction in lead times will allow for deliveries within three weeks for all OssDsign Cranial PSI orders and across all geographies which will increase relevance for more cases.

IMPORTANT EVENTS AFTER THE END OF THE FIRST QUARTER

OssDsign reaches commercial milestone of 750 Cranial PSI sold in Germany

On April 27, OssDsign announced that the company had reached the commercial milestone of 750 Cranial PSI sold in Germany since market entry, with a significant acceleration in sales during the last two years.

1,000 patients treated with OssDsign Catalyst in the U.S.

On May 9, OssDsign announced that 1,000 patients had been treated in the U.S. with the innovative nanosynthetic bone graft OssDsign Catalyst. Product awareness is increasing considerably, which is reflected in the rapidly growing number of patients treated.

OTHER DISCLOSURES

Ownership structure

At the end of the first quarter, there were 2,373 shareholders in OssDsign AB, of which the seven largest shareholders owned more than 5.0% each and together more than 55.0% of the capital and voting rights. The total number of shares was 71,343,130. The largest shareholders on March 31, 2023, were TAMT AB, Karolinska Development AB and SEB Venture Capital.

Group structure

OssDsign AB is the parent company of the Group which, in addition to OssDsign AB, consists of the wholly owned subsidiaries OssDsign Ltd with its registered office in England, OssDsign USA Inc with its registered office in Maryland, USA, and Sirakoss Ltd with its registered office in Scotland. OssDsign's operations are mainly conducted through the parent company OssDsign AB, based in Uppsala.

Employees

At the end of the period, there were a total of 52 (49) employees, of whom 46% were women. This includes employees at the office and production plants in Uppsala and Aberdeen, as well as sales representatives in Germany, France, the U.K. and the U.S.

Financing

The Board regularly reviews the company's existing and forecasted cash flows to ensure that the company has the funds and resources required to conduct the business and the strategic direction decided by the Board. The company's long-term cash requirements are largely determined by how successful current and future products are on the market. As of March 31st, 2023, the group's cash and cash equivalents amounted to SEK 95.6 Million. Based on the sales development of the company's products the board has confidence in the company's mid-long term ability to become profitable and cash flow positive.

Transactions with related parties

The subsidiaries OssDsign USA Inc, OssDsign Ltd and Sirakoss Ltd invoice their costs to the parent company in accordance with transfer pricing agreements.

As of the closing date, the Parent Company has a claim on OssDsign USA Inc of TSEK 3,193, a claim of OssDsign Ltd of TSEK 144 and a claim on Sirakoss Ltd of TSEK 229.

Risks and uncertainties

OssDsign risks and uncertainties include, but are not limited to, financial risks such as future financing, foreign exchange and credit risks. In addition to market risks, there are risks related to OssDsign operations, such as obtaining the necessary government licenses, product development, patents and intellectually property rights, product liability and forward-looking information that may affect the Company.

In addition, developments in 2022 also introduced war, inflation, energy cost increases and interest rate risks to the agenda, all of which may come to affect access to raw materials, distribution, cost of goods and services, as well as customer demand and access to capital. Further information regarding the Company's risk exposure can be found on pages 36 and 77-80 of the OssDsign Annual Report 2022.

Post-pandemic risks related to COVID-19 should still be recognized, insofar as continued staff shortages and delays to hospital approval processes could negatively impact the company's result.

Consolidated summary income statement

SEK 000'	2023	2022	2022
	Jan 1 – Mar 31	Jan 1 – Mar 31	Jan 1 – Dec 31
Net sales	21 466	7 076	56 985
Other income	31	1 245	15 743
Change of inventory items during manufacture, finished goods and work in progress on behalf of others	–	–	–
Cost of material	-3 326	-1 679	-11 850
Other external expenses	-19 688	-12 520	-64 356
Personnel costs	-20 126	-15 339	-74 001
Depreciation, amortization and impairment of tangible and intangible fixed assets/non-financial assets	-2 337	-2 436	-9 718
Impairment losses on financial assets	-28	-87	77
Other expenses	310	-297	-3 295
Operating profit	-23 697	-24 037	-90 494
<i>Profit from financial items</i>			
Net interest income	-97	-44	-9 135
Profit after financial items	-23 794	-24 080	-99 629
Tax expense	542	127	242
Profit for the period	-23 252	-23 953	-99 388
<i>Earnings per share</i>			
Basic earnings per share, SEK	-0.3	-0.4	-1.7

Consolidated summary statement of comprehensive income

SEK 000'	2023	2022	2022
	Jan 1 – Mar 31	Jan 1 – Mar 31	Jan 1 – Dec 31
Profit/loss for the period	-23 252	-23 953	-99 388
<i>Other comprehensive income for the period</i>			
Items that will be reclassified subsequently to profit or loss	-37	78	1 044
Income tax relating to items that will be reclassified	–	–	–
Other comprehensive income for the period	-37	78	1 044
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	-23 289	-23 875	-98 344

Consolidated summary balance sheet

	2023	2022	2022
SEK 000'	March 31	March 31	Dec 31
ASSETS			
<i>Fixed assets</i>			
Intangible fixed assets	152 386	158 336	153 866
Tangible fixed assets	12 799	16 187	13 539
Financial assets	2 503	2 505	2 885
Total fixed assets	167 687	177 028	170 290
<i>Current assets</i>			
Inventories	5 148	2 804	4 418
Current receivables	14 239	7 391	13 220
Other receivables	2 862	1 973	2 134
Prepaid expenses and other accrued income	3 177	2 803	3 409
Cash equivalents	95 611	127 393	124 653
Total current assets	121 037	142 364	147 834
TOTAL ASSETS	288 724	319 392	318 124

	2023	2022	2022
SEK 000'	March 31	March 31	Dec 31
SHAREHOLDER EQUITY AND LIABILITIES			
Equity	203 444	238 926	226 734
Total equity	203 444	238 926	226 734
<i>Long-term liabilities</i>			
Liabilities to credit institutions	599	1 112	727
Lease liabilities	9 151	11 765	9 779
Other liabilities	50 654	49 003	51 164
Total long-term liabilities	60 403	61 880	61 670
<i>Current liabilities</i>			
Liabilities to credit institutions	513	567	513
Accounts payable	6 083	3 875	5 757
Lease liabilities	2 615	2 644	2 581
Current tax liability	455	-	98
Other liabilities	2 079	1 327	1 866
Accrued expenses and deferred income	13 132	10 172	18 906
Total current liabilities	24 877	18 586	29 720
Total liabilities	85 280	80 466	91 390
TOTAL EQUITY AND LIABILITIES	288 724	319 392	318 124

Consolidated change in shareholder's equity in summary

<i>SEK 000'</i>	Share Capital	Subscribed Capital Unpaid	Other Capital Contributions	Reserves	Profit (loss) brought forward	Total Equity
Opening balance 2022-01-01	3 567	-	597 466	286	-338 598	262 722
Profit/loss for the period	-	-	-	-	-23 953	-23 953
Other comprehensive income	-	-	-	78	-	78
Total comprehensive income	-	-	-	78	-23 953	-23 875
<i>Transactions with shareholders</i>						
Warrant program	-	-	-	-	80	80
New share issue	-	-	-	-	-	-
Issue expenses	-	-	-	-	-	-
Total transactions with shareholders	-	-	-	-	80	80
CLOSING BALANCE 2022-03-31	3 567	-	597 466	364	-362 471	238 926
Opening balance 2023-01-01	4 459	-	658 492	1 330	-437 547	266 734
Profit/loss for the period	-	-	-	-	-23 252	-23 252
Other comprehensive income	-	-	-	-39	-	-39
Total comprehensive income	-	-	658 492	-39	-23 252	-23 290
<i>Transactions with shareholders</i>						
Warrant programmes	-	-	-	-	-	-
New share issue	-	-	-	-	-	-
Issue expenses	-	-	-	-	-	-
Total transactions with shareholders	-	-	-	-	-	-
CLOSING BALANCE 2023-03-31	4 459	-	658 492	1 291	-460 798	203 444

Consolidated summary statement of cash flows

	2023	2022	2022
SEK 000'	Jan 1 – Mar 31	Jan 1 – Mar 31	Jan 1 – Dec 31
Operating activities			
Profit after financial items	23 794	-24 080	-99 629
Non cash adjustments	1 700	1 773	9 253
Income tax paid	773	-43	-545
	-21 321	-22 350	-90 922
Change in inventory	-745	-669	-2 267
Change in receivables	-1 631	2 003	-3 180
Change in liabilities	-5 166	-2 856	7 141
Total change in working capital	-7 542	-1 522	1 947
Cash flow from operating activities	-28 863	-23 872	-89 229
Investment activities			
Acquisition of intangible fixed assets	-	-	-
Acquisition of tangible fixed assets	-47	-	-129
Acquisition of group companies	-	-	-
Cash flow from investment activities	-47	-	-129
Financing activities			
New share issue	-	-	65 636
Share issue costs	-	-	-3 717
Warrants	-	80	438
Other change in financial fixed assets	-	-	-
Repayment of borrowing	-128	-209	-513
Cash flow from financing activities	-128	-130	61 843
Cash flow for the period	-29 038	-24 002	-27 515
Cash equivalents at the beginning of the period	124 652	151 366	151 366
Exchange rate differences in cash equivalents	-4	29	548
CASH EQUIVALENTS AT THE END OF THE PERIOD	95 611	127 393	124 653

Summary income statement, parent company

SEK 000'	2023	2022	2022
	Jan 1 – Mar 31	Jan 1 – Mar 31	Jan 1 – Dec 31
Net sales	14 637	6 923	41 743
Other income	31	1 245	14 829
Cost of material	-3 326	-1 797	-10 799
Other external expenses	-22 883	-18 954	-83 260
Personnel costs	-10 558	-10 090	-45 204
Depreciation, amortisation and impairment of tangible and intangible fixed assets/non-financial assets	-172	-281	-891
Other expenses	-81	-171	-2 454
Operating profit	-22 353	-23 125	-86 036
<i>Profit from financial items</i>			
Net interest income	-20	51	-8 948
Profit after financial items	-22 373	-231 074	-94 984
Tax expense	-	-	-
PROFIT FOR THE PERIOD	-22 373	-23 074	-94 984

* Other comprehensive income in the Parent Company is in line with the profit for the period.

Summary balance sheet, parent company

	2023	2022	2022
SEK 000'	Mar 31	Mar 31	Dec 31
ASSETS			
Subscribed capital unpaid	–	–	–
<i>Fixed assets</i>			
Tangible fixed assets	1 405	2 022	1 530
<i>Financial assets</i>			
Shares in group companies	137 687	137 687	137 687
Other long-term receivables	2 314	2 314	2 314
Total financial fixed assets	140 001	140 001	140 002
Total fixed assets	141 407	142 024	141 532
<i>Current assets</i>			
Inventories	4 753	2 463	4 468
Current receivables	4 089	1 854	3 034
Receivables from group companies	7 673	6 703	7 388
Current tax receivables	179	104	541
Other receivables	2 287	1 887	2 117
Prepaid expenses and other accrued income	3 133	2 586	3 333
Cash equivalents	89 667	124 307	120 633
Total current assets	111 781	139 203	141 514
TOTAL ASSETS	253 187	281 927	283 046

	2023	2022	2022
SEK 000'	Mar 31	Mar 31	Dec 31
SHAREHOLDER EQUITY AND LIABILITIES			
<i>Equity</i>			
Restricted equity	4 459	3 567	4 459
Non-restricted equity	182 945	215 843	205 319
Total equity	187 403	219 411	209 778
<i>Provisions</i>			
Other provisions	46 950	44 394	46 950
Total Provisions	46 950	44 394	46 950
<i>Long-term liabilities</i>			
Liabilities to credit institutions	599	1 112	727
Other liabilities	–	–	–
Total long-term liabilities	599	1 112	727
<i>Current liabilities</i>			
Liabilities to credit institutions	513	513	513
Accounts payable	3 618	3 692	5 508
Liabilities to group companies	3 735	3 137	3 994
Current tax liabilities	–	–	–
Other current liabilities	1 891	1 258	1 707
Accrued expenses and deferred income	8 478	8 410	13 869
Total current liabilities	18 235	17 010	25 591
Total liabilities	18 834	18 122	26 318
TOTAL EQUITY AND LIABILITIES	253 187	281 927	283 046

Notes

Note 1 | Accounting Principles

This summary interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and applicable regulations in the Swedish Annual Accounts Act. The interim report for the Parent Company has been prepared in accordance with the Swedish Annual Accounts Act chapter 9, Interim Financial Reporting. The same accounting and valuation policies have been applied for the Group and the Parent Company as in the latest Annual Report, with the exception of the income statement, where change in inventory of finished goods and work in progress is no longer presented. This voluntary change of accounting principle provides the reader with a truer picture, more in line with practice. The effects on the comparison period are presented in the table below. Disclosures in accordance with IAS 34.16A occur in the financial reports and the accompanying notes, and also in other parts of the interim report.

INCOME STATEMENT EFFECT

SEK 000'	Jan – Mar	
	2022 current	2022 previous
Other income	1 245	1 799
Cost of material	-1 679	-2 233

Note 2 | Estimates and assessments

Estimates and assessments are evaluated on an ongoing basis and are based on historical experience and other factors, including expectations of future events that are considered reasonable under prevailing conditions. There has been no change in the estimates and judgments made in the Annual Report for 2022.

Note 3 | Information regarding operating segments

The Group's operations are divided into operating segments based on the parts of the business the Company's highest executive decision-maker follows up, so called "management approach". The Group's internal reporting is based on the Group management following up the operation as a whole. Based on its internal reporting, the Group has identified that the Group has only one segment.

Income from external customers has been attributed to individual countries from which the sales has taken place. The Group's fixed assets are located to Sweden, the U.K. and the U.S.

NET SALES BY GEOGRAPHIC MARKET

SEK 000'	Jan – Mar		Jan – Dec
	2023	2022	2022
USA	14 056	2 816	32 546
EMEA	7 306	4 219	23 917
APAC	104	41	522
TOTAL	21 466	7 076	56 985

Income from external customers has also been attributed to the two product categories in which the company operates, CMF and Orthobiologics.

NET SALES BY PRODUCT CATEGORY

SEK 000'	Jan – Mar		Jan – Dec
	2023	2022	2022
CMF	12 662	6 343	39 944
Orthobiologics	8 804	733	17 041
TOTAL	21 466	7 076	56 985

Note 4 | Equity

The share capital of the Parent Company consists only of fully paid ordinary shares with a nominal (quota value) value of SEK 0.0625 / share. The company has 71,343,130 class A shares.

	2023	2022
	Jan 1 – Mar 31	Jan 1 – Mar 31
Subscribed and paid shares		
At the beginning of the period	71 343 130	57 074 504
Subscribed and paid shares	71 343 130	57 074 504
Shares for share-based payments	–	–
SUM AT THE END OF THE PERIOD	71 343 130	57 074 504

Amounts received for issued shares in addition to the nominal value during the year (premium) are included in the item "Other contributed capital", after deduction for registration and other similar fees and after deduction for attributable tax benefits.

Signatures

The Board of Directors and the CEO provide their assurance that this interim report provides an accurate view of the operations, position and earning of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

This report has been prepared in both a Swedish and an English version. In the event of any discrepancy between the two, the Swedish version shall apply. This report has not been audited.

Financial calendar

Annual General Meeting 2023	May 31, 2023
Interim Report Q2, 2023	August 22, 2023
Interim Report Q3, 2023	November 21, 2023

OSSDSIGN AB – UPPSALA, MAY 23, 2023

Simon Cartmell
Chairman of the Board

Viktor Drvota
Board member

Newton Aguiar
Board member

Anders Qvarnström
Board member

Håkan Engqvist
Board member

Jill Schiaparelli
Board member

Morten Henneveld
CEO




OSSDSIGN®

OssDsign AB, Rapsgatan 23 A, SE 754 50 Uppsala, Sweden

+46(0)18-55 39 93

info@ossdsign.com

ossdsign.com



CONTACT

Morten Henneveld, CEO

+46(0)73 382 43 90

morten.henneveld@ossdsign.com

Anders Svensson, CFO

+46(0)70-272 96 40

anders.svensson@ossdsign.com